Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. (September 2017)

• Record Type: Journal Article
• Authors: Hata, Akito; Katakami, Nobuyuki; Nanjo, Shigeki; Okuda, Chiyuki; Kaji, Reiko; Masago, Katsuhiro; Fujita, Shiro; Yoshida, Hiroshi; Zama, Kota; Imai, Yukihiro; Hirata, Yukio
• Is Part Of: Lung cancer. Volume 111(2017)
• Page Start: 182
• Page End: 189
• Publication Date: 2017-09
• Subjects: Programmed death-ligand 1 -- T790M -- Epidermal growth factor receptor mutation -- Non-small cell lung cancer -- Rebiopsy; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2017.07.022
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: T790M+ status was correlated to lower PD-L1 expression. PD-L1 expression seems to be dynamic and affected by EGFR-TKI treatment. PD-L1 expression might have a prognostic value and interaction with T790M. Abstract: Background: Differential biology and prognosis between T790M+ and T790M- populations imply immunological differences also. Methods: We retrospectively analyzed programmed death-ligand 1 (PD-L1) expression and T790M status in rebiopsied samples of epidermal growth factor receptor ( EGFR )-mutant non-small cell lung cancer (NSCLC). PD-L1 immunohistochemistry was performed using the SP142 antibody for tumour cell (TC) and tumour-infiltrating immune cell (IC) and the 28-8 antibody for TC. PD-L1+ was defined as TC or IC ≥1%. Results: We investigated 67 available rebiopsied histologic samples in 47 patients. Using the SP142, prevalence of PD-L1 any+, moderate+, and strong+ in T790M+ vs. T790M- samples were 31% vs. 61%, 8% vs. 15%, and 0% vs. 2%, respectively, representing PD-L1+ prevalence of T790M+ samples was significantly lower than that of T790M- ( p = 0.0149). Prevalence of any TC+/IC+ in T790M+ vs. T790M- samples were TC: 31% vs. 51% ( p = 0.0997) and IC: 8% vs. 27% ( p = 0.0536), respectively. Using the 28-8, median percentage of PD-L1+ in T790M+ samples was 1.9 (range, 0–27.2), whereas T790M- was 4.1 (range, 0–89.8) ( p = 0.0801). Prevalence of PD-L1+ ≥1%, ≥5%, and ≥10% in T790M+ vs. T790M- samples were 77% vs. 83% ( p = 0.5476), 31% vs. 49% ( p = 0.1419), and 12% vs. 27% ( p = 0.1213), respectively. In 9 of 11 patients receiving multiple rebiopsies, T790M and/or PD-L1 expression revealed temporal dynamism. Survival curves according to PD-L1 expression/T790M status suggested better prognosis in PD-L1-/T790M+ population. Conclusions: T790M+ status was correlated to lower PD-L1 expression. PD-L1 expression might have a prognostic value and interaction with T790M mutation in EGFR -mutant NSCLC.